Healthcare provider profile · identity verified

Jocelyn Morin, MD

Family Practice · CAZENOVIA, NY · NPI 1861875437

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	241	82
Amlodipine Besylate	Amlodipine Besylate	206	72
Levothyroxine Sodium	Levothyroxine Sodium	177	51
Lisinopril	Lisinopril	170	52
Omeprazole	Omeprazole	114	39
Rosuvastatin Calcium	Rosuvastatin Calcium	112	34
Losartan Potassium	Losartan Potassium	108	37
Hydrochlorothiazide	Hydrochlorothiazide	91	31
Gabapentin	Gabapentin	85	25
Metformin Hcl	Metformin Hcl	82	31
Metoprolol Succinate	Metoprolol Succinate	80	27
Trazodone Hcl	Trazodone Hcl	75	22
Simvastatin	Simvastatin	71	18
Duloxetine Hcl	Duloxetine Hcl	70	17
Metformin Hcl Er	Metformin Hcl	70	21
Albuterol Sulfate Hfa	Albuterol Sulfate	58	27
Escitalopram Oxalate	Escitalopram Oxalate	56	19
Famotidine	Famotidine	55	17
Meloxicam	Meloxicam	54	24
Allopurinol	Allopurinol	53	15
Bupropion Xl	Bupropion Hcl	50	16
Alendronate Sodium	Alendronate Sodium	46	16
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	45	suppressed
Ozempic	Semaglutide	45	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	43	14
Sertraline Hcl	Sertraline Hcl	42	12
Zolpidem Tartrate	Zolpidem Tartrate	42	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	41	13
Atenolol	Atenolol	36	suppressed
Furosemide	Furosemide	35	17
Fluoxetine Hcl	Fluoxetine Hcl	34	suppressed
Fluticasone Propionate	Fluticasone Propionate	34	15
Potassium Chloride	Potassium Chloride	33	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	32	24
Prednisone	Prednisone	32	20
Olmesartan Medoxomil	Olmesartan Medoxomil	31	12
Montelukast Sodium	Montelukast Sodium	30	suppressed
Tizanidine Hcl	Tizanidine Hcl	29	14
Eliquis	Apixaban	27	suppressed
Glipizide	Glipizide	26	suppressed
Clopidogrel	Clopidogrel Bisulfate	23	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	23	suppressed
Glipizide Er	Glipizide	23	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	23	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	23	suppressed
Pravastatin Sodium	Pravastatin Sodium	22	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	22	suppressed
Irbesartan	Irbesartan	21	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	21	suppressed
Alprazolam	Alprazolam	20	suppressed
Warfarin Sodium	Warfarin Sodium	20	suppressed
Fluconazole	Fluconazole	19	suppressed
Januvia	Sitagliptin Phosphate	19	suppressed
Jardiance	Empagliflozin	18	suppressed
Risedronate Sodium	Risedronate Sodium	18	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	17	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	17	suppressed
Telmisartan	Telmisartan	17	suppressed
Carbamazepine	Carbamazepine	16	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	16	suppressed
Clonidine	Clonidine	15	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	15	suppressed
Valsartan	Valsartan	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Levetiracetam	Levetiracetam	14	suppressed
Ezetimibe	Ezetimibe	13	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	13	suppressed
Pregabalin	Pregabalin	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	12	suppressed
Promethazine Hcl	Promethazine Hcl	12	suppressed
Spironolactone	Spironolactone	12	suppressed
Tramadol Hcl	Tramadol Hcl	12	suppressed
Carvedilol	Carvedilol	11	suppressed
Cephalexin	Cephalexin	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Lovastatin	Lovastatin	11	suppressed
Nystatin	Nystatin	11	suppressed
Potassium Citrate Er	Potassium Citrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error